Aclairo Pharma Dev. Group

Executive Summary

Aclairo Pharma Dev. Group is a specialized regulatory consulting and drug development services firm founded in 2004 and headquartered in Vienna, USA. The company leverages decades of collective experience from former FDA reviewers, industry scientists, and operational strategists to provide comprehensive non-clinical pharmacology, toxicology, ADME, and pharmaceutical development services, with a particular emphasis on cell and gene therapies. Aclairo supports biotech and pharmaceutical clients across the preclinical stage, helping them navigate complex regulatory pathways to accelerate drug development. By integrating deep scientific expertise with strategic regulatory insight, the firm aims to reduce development risks and improve the probability of successful regulatory submissions. As a private, preclinical-stage service provider, Aclairo’s growth is driven by increasing outsourcing of regulatory functions by drug developers and the rising complexity of cell and gene therapy regulations. The company's established track record and FDA insider knowledge position it well to capture market share in the niche of high-stakes regulatory consulting. While the firm does not disclose financial details, its long-standing presence suggests steady operations. Aclairo is well-positioned to benefit from the growing demand for specialized regulatory expertise, but limited public information constrains visibility into near-term milestones.

Upcoming Catalysts (preview)

• Q3 2026Announcement of a Major Client Engagement in Cell & Gene Therapy70% success
• Q4 2026Expansion of Service Offerings to Include AI-Driven Regulatory Analytics50% success
• Q2 2026Appointment of Former FDA Senior Official as Advisory Board Member65% success